Abstract
An amendment to the original study, "Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines," has been published. This correction addresses labeling errors in the gene expression profiles associated with afatinib treatment.
Introduction
The original research aimed to map the molecular mechanisms of three targeted therapies—trastuzumab, cetuximab, and afatinib—in gastric cancer cell lines (MKN1, NCI-N87, and MKN7). These drugs target the HER2 and EGFR pathways, which are critical in gastric cancer progression. However, the precise effects on protein signaling and gene expression can vary significantly across different cancer cell types.
This correction was issued to rectify labeling errors in the original Table 5. In genomic research, accurately identifying whether a gene is upregulated or downregulated is essential for understanding a drug's mechanism of action. This update ensures that the candidate genes identified as drivers of clinical effects are correctly categorized.
Methodology
The study utilized a combination of phosphoprotein analysis, gene expression profiling, and phenotypic assays. Gastric cancer cell lines were treated with afatinib alone or in combination with trastuzumab. Researchers monitored phenotypic responses, specifically changes in cell motility and the induction of apoptosis (programmed cell death). Gene expression was profiled at 4-hour and 24-hour intervals to identify correlations between transcriptomic changes and physical cellular responses.
Key Results and Gene Expression Profiles
The corrected data provides a definitive list of candidate genes involved in the phenotypic response to afatinib treatment.
Reduction of Motility
In MKN1 cells, 14 candidate genes were identified as being involved in the reduction of cell motility after 4 hours of treatment. Most of these genes, including SERPINE1, HBEGF, and CXCL8, are downregulated (indicated by italics in the data). Conversely, SEMA6D was identified as an upregulated gene (indicated by bold typeface) during this process.
Induction of Apoptosis
The induction of apoptosis was observed specifically in NCI-N87 cells after 24 hours of treatment. A total of 44 candidate genes were identified. While the majority of these genes (e.g., BAX, FAS) are downregulated, a select group of mediators—BBC3, INHBB, NFATC4, and ZNF205—are upregulated, suggesting they play a key role in afatinib-induced cell death.
Discussion and Clinical Implications
The results underscore the heterogeneity of gastric cancer. The fact that the apoptotic response was specific to the NCI-N87 cell line suggests that therapeutic efficacy may depend heavily on the specific genetic background of the tumor.
While these candidate genes provide a roadmap for understanding afatinib's mechanism, further functional validation (such as CRISPR-based studies) is necessary to confirm causality. Additionally, while these in vitro findings are promising, clinical studies are required to determine if these gene expression patterns serve as reliable biomarkers in patients.
Summary updated